TGTX Capital Surpluse from 2010 to 2025

TGTX Stock  USD 29.55  0.41  1.41%   
TG Therapeutics Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse is likely to outpace its year average in 2025. During the period from 2010 to 2025, TG Therapeutics Capital Surpluse regression line of annual values had r-squared of  0.91 and arithmetic mean of  783,284,455. View All Fundamentals
 
Capital Surpluse  
First Reported
2011-06-30
Previous Quarter
1.6 B
Current Value
1.7 B
Quarterly Volatility
579.4 M
 
Yuan Drop
 
Covid
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 510.8 K, Interest Expense of 15.2 M or Total Revenue of 282.1 M, as well as many indicators such as Price To Sales Ratio of 8.87, Dividend Yield of 4.0E-4 or PTB Ratio of 14.28. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of TG Therapeutics over the last few years. It is TG Therapeutics' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

TGTX Capital Surpluse Regression Statistics

Arithmetic Mean783,284,455
Geometric Mean320,821,099
Coefficient Of Variation93.92
Mean Deviation659,499,735
Median552,531,000
Standard Deviation735,641,586
Sample Variance541168.5T
Range1.9B
R-Value0.95
Mean Square Error52226.4T
R-Squared0.91
Slope147,392,622
Total Sum of Squares8117528.1T

TGTX Capital Surpluse History

20251.9 B
20241.8 B
20221.6 B
20211.6 B
20201.5 B
2019740 M
2018552.5 M

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse1.8 B1.9 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.